Brief: IRLAB Gets Positive Feedback On Phase III Program For Mesdopetam From EMA

IRLAB Therapeutics AB

20/02/2025 06:01

Feb 20 (Reuters) - IRLAB Therapeutics AB  IRLABa.ST :
    * EMA PROVIDES POSITIVE FEEDBACK ON IRLAB'S PHASE III
PROGRAM FOR
MESDOPETAM

Source text:  ID:nMFN2bqWDC 
Further company coverage:  IRLABa.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))